interleukin-2 gene
Gene therapyexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 1991 (NCT00002748)
Timeline
Indications
Mechanism of action
- Interleukin-2Supplementation
IL2 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- interleukin-2 gene
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04911166 | Phase 1 | Oct 14, 2021 | Genentech, The University of Texas, Dallas |
| NCT00062036 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2003 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00006033 | Phase 2 | Jun 1, 2000 | National Cancer Institute (NCI), University of South Florida |
| NCT00002748 | Phase 1 | Dec 1, 1991 | National Cancer Institute (NCI), St. Jude Children's Hospital |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 1991 |
| Genentech | For profit | 1 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2003 |
| St. Jude Children's Hospital | Academic/Hospital | 1 | 1 | 1 | 1991 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2000 |
6 organizations
Page 1 / 1